SPDR Dow Jones Industrial Average ETF

SPDR S&P 500 ETF Trust

Invesco QQQ Trust Series 1

NIO, Inc. is a holding company which engages in the design, manufacture, and sale of electric vehicles. Its products include the EP9 supercar and ES8 7-seater SUV. It provides users with home charging, power express valet services, and other power solutions including access to public charging, access to power mobile charging trucks, and battery swapping. It also offers other value-added services such as service package, battery payment arrangement, and vehicle financing and license plate registration. The company was founded by Bin Li and Li Hong Qin on November 28, 2014 and is headquartered in Jiading, China.

NIO Inc - ADR

NIO Inc

NIO is trending following impressive vehicle delivery numbers for December and Q4, surpassing expectations and fueling community excitement about its substantial year-over-year growth and nearing a million cumulative deliveries. The stock's undervaluation is a key talking point, with many anticipating future profitability bolstered by extended EV subsidies and the unique battery swap infrastructure, despite ongoing debates about market manipulation.

Dogecoin is a cryptocurrency based on the popular "Doge" Internet meme and features a Shiba Inu on its logo. Dogecoin is a Litecoin fork. Introduced as a "joke currency" on 6 December 2013, Dogecoin quickly developed its own online community and reached a capitalization of US$60 million in January 2014. Compared with other cryptocurrencies, Dogecoin had a fast initial coin production schedule: 100 billion coins were in circulation by mid-2015, with an additional 5.256 billion coins every year thereafter. As of 30 June 2015, the 100 billionth Dogecoin had been mined.   Dogecoin was created by Billy Markus from Portland, Oregon and  Jackson Palmer from Sydney, Australia. Both wanted to create a fun cryptocurrency that will appeal beyond the core Bitcoin audience. Dogecoin is primarily used as a tipping system on Reddit and Twitter where users tip each other for creating or sharing good content. The community is very active in organising fundraising activities for deserving causes.  The developers of Dogecoin haven’t made any major changes to the coin since 2015. This means that Dogecoin could get left behind and is why Shibas are leaving Dogecoin to join more advanced platforms like Ethereum. One of Dogecoin strengths is its relaxed and fun-loving community. However, this is also a weakness because other currencies are way more professional.  To purchase Dogecoin, it involves downloading a crypto wallet, setting up a crypto exchange account and then trading away for your desired crypto currency. Once we have set up an account with a DOGE currency exchange and deposited some funds, you are ready to start trading.

Dogecoin

Dogecoin is trending with mixed community sentiment as the new year unfolds, fueled by widespread speculation regarding its immediate price action. Enthusiasts are vocal about their hopes for a significant rally, anticipating fresh buying interest as year-end tax adjustments conclude. The ongoing conversation reflects both strong community loyalty and debates surrounding its long-term trajectory as a prominent meme coin.

XPeng, Inc. engages in the design, development, manufacture, and marketing of smart electric vehicles. Its products are environmentally friendly vehicles, namely an SUV (the G3) and a four-door sports sedan (the P7). It also provides a range of services to the clients, including supercharging service, maintenance service, ride-hailing service and vehicle leasing service. The company was founded by Xiao Peng He, Heng Xia, and Tao He in 2015 and is headquartered in Guangzhou, China.

XPeng Inc - ADR

XPeng is actively trending due to its Q3 earnings, significant advancements in AI and humanoid robotics, and strong pre-order demand for its new X9 EREV hybrid. Community sentiment is divided, with many citing undervaluation and global expansion as key bullish drivers, while others point to frustrating price drops and perceived market manipulation in the Chinese EV sector. Attention remains on upcoming delivery figures and the company's path to sustained profitability amidst new EV incentives.

SoundHound AI, Inc. engages in the development, owning, and commercialization of voice, sound, and natural language artificial intelligence technologies and related activities. The company was founded on September 2, 2005 and is headquartered in Santa Clara, CA.

SoundHound AI Inc - Ordinary Shares - Class A

SoundHound AI Inc

SoundHound AI is actively discussed as investors weigh its significant price decline against upcoming catalysts like CES 2026, where bulls anticipate new partnerships and growth announcements. The community is sharply divided, with optimists pointing to strong revenue performance and a substantial contract backlog, while bears express concern over a recent lack of communication and notable insider selling that has fueled skepticism about the company's trajectory within the broader AI sector.

What is Amp?  Amp is described as the new digital collateral token offering instant, verifiable assurances for any kind of value transfer. Using Amp, networks like Flexa can quickly and irreversibly secure transactions for a wide variety of asset-related use cases.  How does Amp work?  Amp claims to offer a straightforward but versatile interface for verifiable collateralization through a system of collateral partitions and collateral managers. Where collateral partitions can be designated to collateralize any account, application, or even transaction, and carry balances which are directly verifiable on the Ethereum blockchain, collateral managers are smart contracts that can lock, release, and redirect collateral in these partitions as needed in order to support value transfer activities. Amp supports a wide variety of use cases for collateralization, and also introduces the concept of predefined partition strategies, which can enable special capabilities such as collateral models through which tokens can be staked without ever leaving their original address.

AMP Token

AMP Crypto is trending amid volatile price surges, igniting intense debate among investors. Bulls point to Flexa's expanding real-world utility, recent partnerships, and patents as catalysts for future growth, while a vocal segment of the community dismisses current movements as short-lived "pump and dump" scams, citing years of sustained losses. This divergence reflects the broader altcoin market's uncertainty and the token's highly polarized sentiment regarding its long-term viability.

Xeris Biopharma Holdings, Inc. is a biopharmaceutical company, which engages in developing and commercializing products across a range of therapies. The company has three commercial products: Gvoke, Keveyis, and Recorlev. Gvoke is ready-to-use liquid glucagon for the treatment of severe hypoglycemia. Keveyis is the therapy approved in the United States to treat hyperkalemic, hypokalemic, and related variants of primary periodic paralysis (PPP). Recorlev is a cortisol synthesis inhibitor approved for the treatment of endogenous hypercortisolemia in adult patients with Cushing’s syndrome. Its product also includes Ogluo which is used for the treatment of severe hypoglycemia in adults, adolescents, and children aged 2 years and over with diabetes mellitus. The company was founded by Steven Prestrelski in 2005 and is headquartered in Chicago, IL.

Xeris Biopharma Holdings Inc

Xeris Biopharma is trending following news that a competitor's Cushing's syndrome treatment received a Complete Response Letter from the FDA, clearing a significant pathway for Xeris's approved drug, Recorlev. This development has ignited community discussions about Recorlev's enhanced market opportunity and is drawing increased attention to the company's broader pipeline, including the anticipated Phase 3 trial for XP-8121.

Bonk is a dog-themed memecoin on the Solana blockchain, launched on Christmas Day 2022 to revitalize the Solana community following the FTX collapse. Created by an anonymous team of 22 Solana developers and builders, Bonk distributed 50% of its total 100 trillion token supply via airdrop to community members including NFT collectors, developers, and artists.   The project positions itself as "the first Solana dog coin for the people, by the people," explicitly rejecting venture capital backing in favor of grassroots community ownership. What sets Bonk apart from other memecoins is its combination of fair launch mechanics, extensive ecosystem integration, and active deflationary strategy.   Built on Solana, BONK benefits from fast transaction speeds and low fees that make it practical for everyday use. Native products include LetsBonk.fun (a memecoin launchpad that briefly became Solana's market leader in 2025, surpassing Pump.fun with over 78% market share), BonkSwap (a decentralized exchange) and BonkBot (a Telegram trading bot with built-in burn mechanics).   BONK is available across 10 blockchain networks and listed on major exchanges including Binance, Coinbase, Kraken, and Robinhood. Governance is handled by BonkDAO, which holds 15% of the token supply and makes decisions through on-chain voting.   The community has organized several major burn events, most notably the December 2024 BURNmas campaign that destroyed 1.69 trillion tokens worth over $50 million. In September 2025, Nasdaq-listed Safety Shot, Inc. formed BONK Holdings LLC and acquired over 2.5% of the circulating supply (valued at $55-63 million), making BONK one of the first memecoins to attract formal corporate treasury adoption. Core contributor Nom was appointed to Safety Shot's board, and the company holds a 10% revenue share in LetsBonk.fun.  As with all memecoins, BONK is a highly speculative asset with substantial volatility. Its value is primarily driven by community sentiment, social media momentum, and meme culture rather than traditional utility.   The anonymous team, while common in the memecoin space, means investors should exercise appropriate caution. Despite these risks, Bonk has established itself as one of the most successful community-driven tokens in the Solana ecosystem, approaching 1 million unique holders and expanding from a simple memecoin into meaningful DeFi infrastructure.

BONK

BONK is trending amid significant community discussion around strategic moves to enhance its utility and institutional presence, particularly with the launch of Europe's first ETP. The community also eagerly anticipates a substantial token burn as it approaches a key holder milestone, fueling mixed sentiment and speculation about a potential rally within the Solana ecosystem.

Li Auto, Inc. engages in the design, development, manufacture, and sale of premium smart electric vehicles. Its products include Li MEGA, a high-tech flagship family MPV, Li L9, a six-seat flagship family SUV, and Li L8, a six-seat premium family SUV, and Li L7, a five-seat flagship family SUV. The firm also offers in-house development efforts on its proprietary range extension system, next-generation electric vehicle technology, and smart vehicle solutions. The company was founded by Xiang Li in April 2015 and is headquartered in Beijing, China.

Li Auto Inc - ADR

Li Auto is seeing significant discussion following an unexpected Q3 loss and a cautious Q4 delivery outlook, which has fueled mixed sentiment within the investor community. Despite these challenges, the launch of the company's new AI-powered smart glasses is generating buzz, while renewed government subsidies for electric vehicles are providing a sector-wide tailwind, influencing views on Li Auto's new i6 SUV and broader market position.

Infinite Money Glitch ($IMG) is revolutionizing DeFi on Solana by leveraging the Token2022 program's advanced tax extension capabilities to create a truly innovative reward system for token holders.  At its core, $IMG implements a seamless 5% tax on all transactions - whether buying, selling, or transferring tokens. This tax is automatically collected and distributed to holders in SOL, creating a sustainable passive income stream for the community. 4.5% of the tax gets sent to holders, while .5% gets sent to an Infrastructure wallet to help with development, marketing and general infrastructure.  What sets $IMG apart is its implementation of Solana's Token2022 program, enabling automated and efficient reward distribution without relying on external smart contracts.

Infinite Money Glitch

IMG CRYPTO is trending due to its "Infinite Money Glitch" protocol, which consistently distributes passive Solana rewards to holders, cultivating a highly dedicated and resilient community. Despite recent chart movements, a strong bullish sentiment persists, fueled by anticipation for upcoming LP rewards, the imminent launch of real-time audit technology, and its ambitious aim to integrate with major gaming economies.

Shiba Inu (SHIB) is a meme token which began as a fun currency and has now transformed into a decentralized ecosystem. During the initial launch, 50% of the supply was allocated into Vitalik Buterin's ethereum wallet.   As a result of that, Vitalik proceeded to donate 10% of his SHIB holdings to a COVID-19 relief effort in India and the remaining 40% is burnt forever. That donation was worth about $1 billion at that time, which makes it one of the largest donation ever in the world.  What is the Shiba Inu community working on right now? The Shiba Inu team launched a decentralized exchange called Shibaswap with 2 new tokens, LEASH and BONE. LEASH is a scarce supply token that is used to offer incentives on Shibaswap. BONE is the governance token for holders to vote on proposals on Doggy DAO.

Shiba Inu

Shiba Inu is currently trending amidst notable price weakness, with community sentiment sharply divided between staunch bearish views labeling it a "scam" and confident calls to "buy the dip" at multi-year lows. Many users express frustration over its prolonged decline, while a dedicated segment highlights long-term conviction and anticipates a significant rebound. This polarization is amplified by broader meme coin market dynamics, including recent selling pressure from activities like year-end tax loss harvesting.

statis crypto Watchlist

Bitcoin

Ethereum

Solana

Ripple

Cardano

statis IN Watchlist

Nifty 50

Nifty Bank

Reliance Industries Ltd.

Zomato Ltd.

Tata Consultancy Services

Tata Motors Ltd.

HDFC Bank Ltd.

ITC Ltd.

Adani Enterprises Ltd

Axis Bank Ltd

Bajaj Finance Ltd

statis US Watchlist

SPDR S&P 500 ETF

Apple Inc.

Tesla Inc

Microsoft Corporation

NVIDIA Corp

 Hey, I want to invite you to join Stocktwits. It’s the largest global community of active traders. You’ll get access to the real-time market insights, news, discussion and much more! You can sign up using my unique link below 
 


 has invited you to join Stocktwits

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update

BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update BioLineRx Reports Third Quarter 2025 Financial Results and Provides Corporate Update PR Newswire TEL AVIV, Israel...

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025

BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 BioLineRx to Report Third Quarter 2025 Results on November 24, 2025 PR Newswire TEL AVIV, Israel, Nov. 18, 2025 Management to Hold...

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types

BioLineRx Announces Receipt of USPTO Notice of Allowance for Key Patent Covering GLIX1 for Treating a Broad Range of Cancer Types BioLineRx Announces Receipt of USPTO Notice of Allowance for Key...

Shares of BioLineRx (BLRX) skyrocketed 32% on Friday after the biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://ir.biolinerx.com/news-releases/news-release-details/biolinerx-announces-new-pilot-phase-data-phase-2-combination">announced</a> positive data from the single-arm pilot phase of its Phase 2 trial evaluating its drug in the treatment of pancreatic cancer.The study is evaluating the company’s Motixafortide, Cemiplimab, and standard-of-care chemotherapies Gemcitabine and Nab-paclitaxel, versus Gemcitabine and Nab-paclitaxel alone, in first-line pancreatic cancer (PDAC).The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year. Progression-free means that the patient's disease did not get worse or spread.CEO Philip Serlin said that the data emerging from the pilot phase of the study are “extremely encouraging,” while also noting that pancreatic cancer is the “most challenging” tumor to treat.The company also stated that it now plans to enroll 108 patients in the Phase 2 trial, which will be a randomized study, based on the results of the pilot phase. The company had previously planned to enroll only 30 patients in the study.The trial is planned to be fully enrolled in 2027. While the trial's primary endpoint is progression-free survival (PFS), secondary objectives include safety, response rate, disease control rate, duration of clinical benefit, and overall survival.Following the news, Jones Research upgraded BioLineRx to ‘Buy’ from ‘Hold’ with a $12 price target. With these results, BioLineRx will have additional opportunities to either partner the asset or fund a pivotal trial, assuming favorable Phase II results, the analyst said.On Stocktwits, retail sentiment around BLRX jumped from ‘bullish’ to ‘extremely bullish’ territory over the past 24 hours while message volume stayed at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:626/68;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_30_at_12_47_05_PM_png_ca2195fcbe.webp" alt="BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits" width="626" height="68"><figcaption>BLRX's Sentiment Meter and Message Volume as of 12:45 p.m. ET on May 30, 2025 | Source: Stocktwits</figcaption></figure> <a href="https://stocktwits.com/symbol/BLRX">BLRX</a> is down by about 50% this year and by about 84% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/gilead-eyeing-hiv-drug-rollout-in-low-income-countries-report/ch0ubVvRbuE">Gilead Eyes HIV Drug Rollout In Low-Income Countries Despite Funding Uncertainty, Says Report: Retail Holds Onto Bearish Stance</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Rising stock market chart on a trading board background.

BioLineRx Stock Jumps On Positive Data from Pilot Phase Of Pancreatic Cancer Drug Trial: Retail Cheers The ‘Buy’ Rating

The company said that updated results from the pilot phase indicate that four of eleven patients remained disease progression-free after more than one year.

Equity

Nasdaq-listed shares of BioLineRx (BLRX) traded 4% higher on Tuesday afternoon after the company reported an over 600% year-on-year jump in its first-quarter net income.The Israel-based biopharmaceutical company <a target="_blank" rel="noopener noreferrer nofollow" href="https://www.prnewswire.com/news-releases/biolinerx-reports-first-quarter-2025-financial-results-and-provides-corporate-update-302465635.html">reported</a> revenues for the three months ended March 31, 2025, of $0.3 million, compared to revenues of $6.9 million in the year-ago period, and below an analyst estimate of $1 million, as per Koyfin data.BioLineRx out-licensed its FDA-approved Aphexda, used in treating a type of cancer called multiple myeloma, to Ayrmid last November and shut its U.S. commercial operations by the year-end.Aphexda, however, generated sales of $1.4 million in the first quarter, providing the company with $0.3 million in royalties.The fall in revenue in the first quarter reflects the company’s change in operation after out-licensing Aphexda, it said.Net income for the quarter ended March 31, 2025, was $5.1 million, compared to $0.7 million for the quarter ended March 31, 2024, and above an estimated net loss of $3 million. The net non-operating income stood at $7.6 million, compared to net non-operating income of $4.5 million in the three months ended March 31, 2024.The company ended the quarter with cash, cash equivalents, and short-term bank deposits of $26.4 million, which it expects to be sufficient through the second half of 2026.CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda."I remain optimistic that we will announce a meaningful transaction this year," he said.On Stocktwits, retail sentiment around BioLineRx rose within the ‘extremely bullish’ territory over the past 24 hours while message volume remained at ‘extremely high’ levels.<figure class="image"><img style="aspect-ratio:627/65;" src="https://news.stocktwits-cdn.com/Screenshot_2025_05_27_at_1_49_08_PM_png_c44b3d7c0e.webp" alt="BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits " width="627" height="65"><figcaption>BLRX's Sentiment Meter and Message Volume as of 1:50 p.m. ET on May 27, 2025 | Source: Stocktwits&nbsp;</figcaption></figure><a href="https://stocktwits.com/symbol/BLRX">BLRX stock</a> is down by about 63% this year and nearly 87% over the past 12 months.Read Next: <a href="https://stocktwits.com/news-articles/markets/equity/byd-sued-by-brazil-prosecutors-for-alleged-human-trafficking/ch0V1GJRbra">BYD Sued By Brazil Prosecutors For Alleged Human Trafficking: Retail’s In Wait-And-Watch Mode</a>For updates and corrections, email newsroom[at]stocktwits[dot]com.

Global stock market chart and trading board - stock photo

BioLineRx Q1 Earnings Rise Despite Fall In Revenue: Retail Stays Super Confident

CEO Philip Serlin said that the company has been actively evaluating new assets in the areas of oncology and rare diseases, where it can leverage its expertise after out-licensing Aphexda. 

BioLineRx Ltd. is a clinical stage biopharmaceutical company, which engages in the research and development of treatments that focus on cancer. Its product pipeline includes Motaxafortide (BL-8040), which is used for stem-cell mobilization, solid tumors, and acute myeloid lukemia; and AGI-134, which is an immunotherapy treatment used for multiple solid tumors. The company was founded in 2003 and is headquartered in Modi'in, Israel.

BLRX
BioLineRx, Ltd.

Feed

News

Sentiment

Earnings

Fundamentals

Info

Latest BLRX News

BLRXBioLineRx, Ltd.